Loading...
XSHG603858
Market cap2.37bUSD
Dec 25, Last price  
16.25CNY
1D
-0.98%
1Q
0.37%
Jan 2017
-77.83%
IPO
-76.14%
Name

Shandong Buchang Pharmaceuticals Co Ltd

Chart & Performance

D1W1MN
XSHG:603858 chart
P/E
54.29
P/S
1.31
EPS
0.30
Div Yield, %
6.90%
Shrs. gr., 5y
-0.63%
Rev. gr., 5y
-0.62%
Revenues
13.25b
-11.41%
5,871,833,2507,036,593,8278,591,698,81310,333,616,10211,655,627,38712,320,883,10113,863,918,66113,664,752,61314,255,454,95916,006,714,33915,762,679,80214,951,252,69413,245,133,302
Net income
319m
1,228,166,4911,251,331,2991,168,574,7541,323,627,3003,536,764,3641,769,364,6461,637,952,3171,888,405,3721,945,997,1731,860,894,3351,162,117,9190318,973,324
CFO
-164m
L
01,349,185,8551,113,956,7901,780,581,7632,120,730,7161,668,783,0821,961,975,6032,050,837,3142,621,333,5281,958,763,3871,320,513,3692,755,627,692-164,259,736
Dividend
Aug 20, 20240.126 CNY/sh

Profile

Shandong Buchang Pharmaceuticals Co., Ltd. engages in the research and development, production, and sale of medicines in China. It offers medicines to treat cardiac and cerebral vascular, urinary and digestive, respiratory, gynecological, and other diseases, as well as diabetes. The company was founded in 1993 and is based in Heze, China. Shandong Buchang Pharmaceuticals Co., Ltd. was a former subsidiary of Shanghai Zhangjiang (Group) Co., Ltd.
URL
http://www.buchang.com/
IPO date
Nov 18, 2016
Employees
Domiciled in
CN
Incorporated in
CN

Valuation

Title
CNY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑122014‑12
Income
Revenues
13,245,133
-11.41%
14,951,253
-5.15%
15,762,680
-1.52%
Cost of revenue
11,277,296
12,242,528
13,101,565
Unusual Expense (Income)
NOPBT
1,967,837
2,708,725
2,661,115
NOPBT Margin
14.86%
18.12%
16.88%
Operating Taxes
242,692
331,594
478,288
Tax Rate
12.33%
12.24%
17.97%
NOPAT
1,725,146
2,377,131
2,182,827
Net income
318,973
 
1,162,118
-37.55%
Dividends
(1,194,264)
(398,175)
(581,778)
Dividend yield
6.35%
1.71%
2.49%
Proceeds from repurchase of equity
(9,990)
BB yield
0.05%
Debt
Debt current
240,117
999,492
1,617,478
Long-term debt
2,263,954
2,179,850
1,940,663
Deferred revenue
2
330,554
345,626
Other long-term liabilities
148,066
144,000
1
Net debt
(272,079)
(418,028)
907,057
Cash flow
Cash from operating activities
(164,260)
2,755,628
1,320,513
CAPEX
(529,915)
Cash from investing activities
(195,058)
Cash from financing activities
(1,069,676)
FCF
1,388,447
2,932,337
1,461,840
Balance
Cash
1,048,223
2,875,140
1,715,875
Long term investments
1,727,926
722,230
935,209
Excess cash
2,113,893
2,849,808
1,862,950
Stockholders' equity
8,313,824
9,868,725
11,991,648
Invested Capital
12,071,956
12,766,519
16,122,041
ROIC
13.89%
16.46%
13.99%
ROCE
13.78%
17.25%
14.71%
EV
Common stock shares outstanding
1,106,010
1,106,043
1,106,043
Price
17.01
-19.04%
21.01
-0.38%
21.09
-8.58%
Market cap
18,813,232
-19.04%
23,237,956
-0.38%
23,326,439
-8.58%
EV
18,300,169
22,819,928
24,258,663
EBITDA
2,560,412
3,206,288
3,171,548
EV/EBITDA
7.15
7.12
7.65
Interest
109,931
135,100
167,288
Interest/NOPBT
5.59%
4.99%
6.29%